Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, discusses data and key points from COVID-19 and Cancer Consortium (CCC19), looking at systemic cancer treatment-related outcomes in patients with COVID-19. Results demonstrated that the patients that had recently received the combination of chemotherapy and immunotherapy within the past 2 weeks, had a higher mortality rate compared to patients who did not receive this. The study identified all of the following as negative prognostic factors in patients with cancer and COVID-19: older age, male sex, black ethnicity, smoker, progressive cancer, performance status, multiple cancers, multiple comorbidities and any recent therapy within the past 3 months. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
